Deutsche Bank turns bearish on Novartis as shares recover failed trial losses
Published . Updated .
Covered by 2 outlets: Yahoo Finance, Investing.com.
Who covered it: Center 2. How we rate outlets
Investing.com -- Deutsche Bank downgraded pharmaceutical company Novartis to “sell” from “hold” and cut its price target to CHF115 from CHF120, saying the shares have more than recovered losses from two failed drug trials.
Directly affected
- NVS Novartis Ag+1.3% 17d
Named in this report.
Indirectly affected
- XLF Financial Select Sector SPDR-3.5% 30d
Financial Select Sector SPDR: it holds banks. Linked by “bank” (banks) in this story.
- KRE SPDR S&P Regional Banking ETF-4.8% 30d
SPDR S&P Regional Banking ETF: it holds banks. Linked by “bank” (banks) in this story.
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story.
- BAC Bank of America-11.1% 30d
Bank of America (national commercial banks): banks' earnings move with lending, deposits and rates. Linked by “bank” (banks) in this story.
- JPM JPMorgan Chase-4.3% 30d
JPMorgan Chase (national commercial banks): banks' earnings move with lending, deposits and rates. Linked by “bank” (banks) in this story.
- WFC Wells Fargo-3.6% 30d
Wells Fargo (national commercial banks): banks' earnings move with lending, deposits and rates. Linked by “bank” (banks) in this story.
- C Citigroup-9.2% 30d
Citigroup (national commercial banks): banks' earnings move with lending, deposits and rates. Linked by “bank” (banks) in this story.
- LLY Eli Lilly and+21.6% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| NVSNo price data for this ticker | — | — | — | — | — | — | — |
| XLFNo price data for this ticker | — | — | — | — | — | — | — |
| KRENo price data for this ticker | — | — | — | — | — | — | — |
| XLVNo price data for this ticker | — | — | — | — | — | — | — |
| BACNo price data for this ticker | — | — | — | — | — | — | — |
| JPMNo price data for this ticker | — | — | — | — | — | — | — |
| WFCNo price data for this ticker | — | — | — | — | — | — | — |
| CNo price data for this ticker | — | — | — | — | — | — | — |
| LLYNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Deutsche Bank turns bearish on Novartis as shares recover failed trial losses Yahoo Finance
Source: Yahoo Finance
Congressional trades in the stocks in this story
- Rep. Kevin Hern sold Novartis Ag (NVS), worth $15,001 - $50,000 on 27 Aug 2026. That is 67 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Bank Of America (BAC) (held by a spouse), worth $1,001 - $15,000 on 9 Sep 2026. That is 54 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Laurel Lee sold Bank Of America (BAC) (held by a spouse), worth $50,001 - $100,000 on 24 Aug 2026. That is 70 days before publication. Filed 16 Oct 2026. View the filing.
- Sen. Sheldon Whitehouse sold Jpmorgan Chase (JPM), worth $15,001 - $50,000 on 4 Sep 2026. That is 59 days before publication. Filed 1 Oct 2026. View the filing.
- Sen. Sheldon Whitehouse sold Jpmorgan Chase (JPM) (held by a spouse), worth $15,001 - $50,000 on 4 Sep 2026. That is 59 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Jpmorgan Chase (JPM) (held by a spouse), worth $100,001 - $250,000 on 27 Aug 2026. That is 67 days before publication. Filed 4 Sep 2026. View the filing.
- Rep. Rohit Khanna bought Wells Fargo (WFC) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 38 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Wells Fargo (WFC) (held by a dependent child), worth $15,001 - $50,000 on 17 Sep 2026. That is 46 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Wells Fargo (WFC) (held by a dependent child), worth $1,001 - $15,000 on 15 Sep 2026. That is 48 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Citigroup (C), worth $1,001 - $15,000 on 24 Sep 2026. That is 39 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Citigroup (C) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 59 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 59 days before publication. Filed 7 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLF)
Companies carried with this story
- XLF Select Sector Spdr Tr
For “Deutsche Bank turns bearish on Novartis as shares recover failed trial losses,” Select Sector Spdr Tr (XLF) is linked, with no stored direction, medium confidence. Reason on file: Financial Select Sector SPDR: it holds banks. Linked by “bank” (banks) in this story
- KRE Spdr Series Trust
For “Deutsche Bank turns bearish on Novartis as shares recover failed trial losses,” Spdr Series Trust (KRE) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Regional Banking ETF: it holds banks. Linked by “bank” (banks) in this story
- BAC Bank Of America
Bank Of America (BAC) is linked, with no stored direction, medium confidence in the 2 Nov 2026 story “Deutsche Bank turns bearish on Novartis as shares recover failed trial losses.” Reason on file: Bank of America (national commercial banks): banks' earnings move with lending, deposits and rates. Linked by “bank” (banks) in this story
- JPM Jpmorgan Chase
Jpmorgan Chase (JPM) is linked, with no stored direction, medium confidence in the 2 Nov 2026 story “Deutsche Bank turns bearish on Novartis as shares recover failed trial losses.” Reason on file: JPMorgan Chase (national commercial banks): banks' earnings move with lending, deposits and rates. Linked by “bank” (banks) in this story
- WFC Wells Fargo
For “Deutsche Bank turns bearish on Novartis as shares recover failed trial losses,” Wells Fargo (WFC) is linked, with no stored direction, medium confidence. Reason on file: Wells Fargo (national commercial banks): banks' earnings move with lending, deposits and rates. Linked by “bank” (banks) in this story
- C Citigroup
In “Deutsche Bank turns bearish on Novartis as shares recover failed trial losses,” Citigroup (C) is linked, with no stored direction, medium confidence. Reason on file: Citigroup (national commercial banks): banks' earnings move with lending, deposits and rates. Linked by “bank” (banks) in this story
Select Sector Spdr Tr (XLF)
On 2 Nov 2026, “Deutsche Bank turns bearish on Novartis as shares recover failed trial losses” is the story that connects Select Sector Spdr Tr (XLF) to this story.
For Select Sector Spdr Tr (XLF), the reason on file says Financial Select Sector SPDR: it holds banks. Linked by “bank” (banks) in this story
A second company, Spdr Series Trust (KRE), is listed for a different reason: SPDR S&P Regional Banking ETF: it holds banks. Linked by “bank” (banks) in this story
Dates in the story, and the Select Sector Spdr Tr (XLF) price range
BAC traded between 49.26 and 54.92 across 20 sessions. The latest close on file is 50.00. KRE traded between 67.80 and 71.93 across 20 sessions. The latest close on file is 70.61. XLF traded between 52.82 and 56.03 across 20 sessions. The latest close on file is 55.07.
What the saved facts support for Select Sector Spdr Tr (XLF)
54 out of 100
“Deutsche Bank turns bearish on Novartis as shares recover failed trial losses” scores 54 out of 100. The score uses 2 sources, and 6 linked companies.